The Life Sciences team advised Cerevance on the closing of its $45 million Series B financing from new investors including GV (formerly Google Ventures), Bill Gates and Foresite Capital, as well as all of the company’s previous investors, which include Takeda Ventures, Inc., the Dementia Discovery Fund and Lightstone Ventures. Cerevance will use the proceeds to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s disease, by transcriptionally and epigenetically profiling specific neuronal and glial cell populations in thousands of post-mortem human brain tissue samples and advancing a diverse portfolio of therapeutic programs against them.
Cerevance is a private, clinical-stage pharmaceutical company focused on brain diseases. The company is applying a new technology, called NETSseq, to reveal transcriptional and epigenetic differences between specific cell types in mature human brains.
The Goodwin team was led by Kingsley Taft, Noelle Dubiansky and Joshua Tarr.
For additional details on the financing round, please read the press release and coverage in FierceBiotech.